Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Cancer（2023）
摘要
In PRIMA, similar dose intensity, similar efficacy, and improved safety were observed with the ISD compared with the FSD regimen.
更多查看译文
关键词
individualized starting dose,niraparib,ovarian cancer,poly(ADP-ribose) polymerase inhibitors/adverse effects,poly(ADP-ribose) polymerase inhibitors/therapeutic use
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要